Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
- A4227 Tipifarnib (Zarnestra)Summary: Farnesyltransferase inhibitor,potent and specific
- A4379 LonafarnibTarget: FPTaseSummary: Ftase inhibitor,potent and selective
- A4381 FK866 (APO866)1 CitationTarget: NamptSummary: NAMPT inhibitor, non-competitive, highly specific
- A4382 A922500Target: DGATSummary: DGAT-1 inhibitor
- A4383 TolcaponeTarget: Catechol O-Methyltransferase (COMT)Summary: COMT inhibitor
- A4384 PF-04620110Summary: DGAT-1 inhibitor,potent and selective
- B5521 LY 78335Summary: phenylethanolamine-N-methyltransferase (PNMT) inhibitor
- B5729 GPP 78 hydrochlorideSummary: NAMPT inhibitor
- B5842 FTI 277 HClSummary: FTase inhibitor
- B6062 Manumycin ASummary: farnesyltransferase inhibitor